Background
==========

Mast cell-associated malignancies are important diseases in both humans and dogs \[[@B1],[@B2]\] and are characterized by activating mutations in KIT in both species. More than 90% of human patients with systemic mastocytosis carry the D816V mutation in *KIT*\[[@B3]\] which results in constitutive activation of KIT signaling and plays a major role in the proliferative phenotype. A functionally identical mutation (D814V) is found in transformed mast cell lines from rodents \[[@B4],[@B5]\]. Similarly, approximately 30% of dogs with high-grade cutaneous mast cell tumors (MCTs) possess activating internal tandem duplications (ITDs) in the KIT juxtamembrane (JM) domain \[[@B6],[@B7]\]. More recently, activating mutations in the extracellular domain of KIT (exons 8 and 9) have also been identified in a proportion of canine MCTs \[[@B8]\]. While the role of KIT dysfunction in mast cell neoplasia has been well described, little is known regarding additional molecular mechanisms that may contribute to invasion and metastasis of malignant mast cells.

The expression of matrix metalloproteinases (MMPs), a family of enzymes involved in the degradation and remodeling of extracellular matrix, has been implicated in the neoplastic transformation of mast cells. Normal canine bone marrow-derived mast cells (BMMCs) produce large quantities of inactive and active MMP9 in response to various stimuli while releasing little detectable MMP2 \[[@B9]\]. Neoplastic mast cells are known to produce both MMP2 and MMP9 \[[@B10]\] suggesting that the ability to produce MMP2 may be a feature acquired by malignant mast cells. Furthermore, high-grade MCTs express significantly higher levels of MMP9 in proactive and active forms, which has been proposed to be associated with the high degree of malignant behavior of these tumors \[[@B10],[@B11]\]. More recently, characterization of the proteome of primary canine low-grade MCTs and aggressive, high-grade MCTs identified differentially expressed proteins between the two groups \[[@B12]\]. Several stress response proteins (HSPA9, TCP1A, TCP1E) and cytoskeletal proteins associated with actin remodeling and cell migration (WDR1) were significantly up-regulated in high-grade MCTs.

MicroRNAs (miRNAs) are highly conserved, noncoding RNAs that serve as important regulators of gene expression. It is well established that miRNA expression is altered in many human malignancies and that miRNAs function as tumor suppressor genes or oncogenes through dysregulation of target genes \[[@B13]\]. Currently there is limited information regarding the potential role of miRNA dysregulation in malignant mast cell disease. Several miRNAs appear to play an important role in normal murine mast cell differentiation \[[@B14]\] and following activation of murine mast cells, up-regulation of the miR-221-222 family influences cell-cycle checkpoints, in part by targeting p27^Kip1^\[[@B15]\]. Basal levels of miR-221 contribute to the regulation of the cell cycle in resting mast cells. However, its effects are activation-dependent and in response to mast cell stimulation; miR-221 regulates degranulation, cytokine production, and cell adherence \[[@B16]\]. More recent studies have demonstrated roles for miR-539 and miR-381 in mediating a novel regulatory pathway between KIT and microphthalmia-associated transcription factor in normal and malignant mast cells \[[@B17]\].

The purpose of this study was to investigate the potential role of miRNA dysregulation in the biologic behavior of primary canine MCTs. We found that unique miRNA expression profiles correlate with the biological behavior of primary canine MCTs and that miR-9 was significantly overexpressed in aggressive MCTs compared to benign MCTs. Furthermore, enforced miR-9 expression in murine mastocytoma cell lines and normal murine BMMCs with low basal levels of miR-9 enhanced invasion and induced the expression of several target genes associated with metastasis, including chymase (CMA1) and heparinase (HSPE). These data suggest that miR-9 overexpression may contribute to the invasive phenotype of malignant mast cells thereby providing a potentially novel pathway for therapeutic intervention in malignant mast cell disease.

Methods
=======

Cell lines, primary cell cultures, primary tumor samples
--------------------------------------------------------

Mouse P815 (D814V *KIT* mutation) and C57 (wild-type *KIT*) cell lines were provided by Dr. Stephen Galli (Stanford University). The canine BR (activating point mutation L575P in the JM domain of *KIT*) and C2 (*KIT* ITD mutation in the JM domain) cell lines were provided by Dr. Warren Gold (Cardiovascular Research Institute, University of California- San Francisco). Cell lines were maintained in RPMI 1640 (Gibco® Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco® Life Technologies) and antibiotics (Gibco® Life Technologies). Mouse BMMCs were generated from bone marrow from C57/B6 wild-type mice as previously described \[[@B9]\]. Canine BMMCs were generated from 2 dogs and maintained in Stemline (Sigma-Aldrich, St. Louis, MO, USA) medium supplemented with recombinant canine stem cell factor (R & D Systems, Minneapolis, MN, USA) as previously described \[[@B18]\]. Protocols for collection of murine bone marrow and canine bone marrow were approved by the Ohio State University (OSU) Institutional Care and Use Committee (IACUC), protocols 2009A0204 and 2010A0015, respectively. Canine MCTs were obtained from 24 different affected dogs presented to the OSU Veterinary Medical Center and University of California-Davis (UCD) Veterinary Teaching Hospital. Tumor sample collections were performed in accordance with established hospital protocols and approved by respective IACUC at both OSU and UCD. Clinical outcome data, including sex, breed, primary tumor location, recurrence and metastasis, histopathologic grade, mitotic index, and outcome was available for all dogs (see Additional file [1](#S1){ref-type="supplementary-material"}). Tumors obtained from dogs that were adequately controlled with surgery alone and did not develop or die from metastatic mast cell disease were considered biologically low-grade tumors (benign). Tumors from dogs that developed aggressive, metastatic mast cell disease which resulted in their death were classified as biologically high-grade tumors.

Quantitative reverse-transcription-PCR profiling of mature miRNA expression in MCT biopsies
-------------------------------------------------------------------------------------------

Total RNA was isolated by the Trizol method (Invitrogen, Carlsbad, CA, USA) and heparinase treated as described \[[@B19]\]. Primary MCT miRNA expression profiling was performed at the OSU Nucleic Acid Shared Resource using the TaqMan Array Human miRNA Panel (Human A Cards, v.2, Applied Biosystems, Foster City, CA, USA) as described previously \[[@B20]\]. This panel assays the expression of 377 human miRNAs, 151 of whose mature sequences are 100% conserved between human and dog (Sanger miRBase v.12). Raw data analysis, normalizer selection and statistical analysis were performed using the real-time PCR analysis software Statminer (Integromics, Madison, WI, USA). The snRNA U6 was confirmed to be stably expressed in our sample set and the mean used as the normalizer value. Relative gene expression was calculated using the comparative threshold cycle method \[[@B21]\]. Gene expression heat maps were generated using Treeview PC-based software \[[@B22]\].

RNA isolation and quantitative real-time PCR
--------------------------------------------

RNA was extracted from cell lines using TRIzol (Invitrogen) and real-time PCR was performed using the Applied Biosystems StepOne Plus Detection System. MiR-9 is highly conserved and shares 100% homology between dogs, humans, and mice. Mature miR-9 expression was performed using Taqman miRNA assays (Applied Biosystems). 50 ng total RNA was converted to first-strand cDNA with miRNA-specific primers, followed by real-time PCR with TaqMan probes. All samples were normalized to U6 snRNA.

Real-time PCR was performed to validate changes in mRNA expression for selected genes affected by miR-9 over expression. cDNA was made from 1 μg of total RNA using Superscript III (Invitrogen). CMA1, HSPE, IFITM3, MLANA, PERP, PPARG, PDZK1IP1, SERPINF1, SLPI, TLR7, CD200R1, CD200R4 and 18S transcripts were detected using Fast SYBR green PCR master mix (Applied Biosystems) according to the manufacturer's protocol; primer sets are detailed in Table [1](#T1){ref-type="table"}. Normalization was performed relative to 18S rRNA. All reactions were performed in triplicate and included no-template controls for each gene. Relative gene expression for all real-time PCR data was calculated using the comparative threshold cycle method \[[@B21]\]. Experiments were repeated 3 times using samples in triplicate.

###### 

Primers for quantitative reverse transcriptase polymerase chain reaction

  **Primers**           **Primer sequences**
  --------------------- -----------------------------------------
  Mouse Cma1 292F       5'-GAA GAC ACG TGG CAG AAG CTT GAG-3'
  Mouse Cma1 521R       5'-GTG TCG GAG GCT GGC TCA TTC ACG-3'
  Mouse Hspe F479       5'-GCT CAG TGG ACA TGC TCT ACA G-3'
  Mouse Hspe R697       5'-GCA ACC CAT CGA TGA GAA TGT G-3'
  Mouse Ifitm3 115F     5'-GCT TCT GTC AGA ACT ACT GTG-3'
  Mouse Ifitm3 339R     5'-GAG GAC CAA GGT GCT GAT GTT CAG-3'
  Mouse Mlana 125F      5'-GCT GCT GGT ACT GTA GAA GAC G-3'
  Mouse Mlana 322R      5'-GTG AAG AGA GCT TCT CAT AGG CAG-3'
  Mouse Pdzk1ip1 F520   5'-GTT CTG GCT GAT GAT CAC TTG ATT G-3'
  Mouse Pdzk1ip1 R769   5'-GAT AGA AGC CAT AGC CAT TGC TG-3'
  Mouse SerpinF1 712F   5'-GTG AGA GTC CCC ATG ATG TCA G-3'
  Mouse SerpinF1 910R   5'-GTT CTC GGT CGA TGT CAT GAA TG-3'
  Mouse Tlr7 F2284      5'-GTC ATT CAG AAG ACT AGC TTC CCA G-3'
  Mouse Tlr7 R2441      5'-GTC ACA TCA GTG GCC AGG TAT G-3'
  Mouse Cd200r1 659F    5'-GTA ACC AAT CTC TGT CCA TAG-3'
  Mouse Cd200r1 902R    5'-GTC ACA GTA TCA TAG AGT GGA TTG-3'
  Mouse Cd200r4 312F    5'-GCC TCC ACA CCT GAC CAC AG-3'
  Mouse Cd200r4 532R    5'-GTC CAA GAG ATC TGT GCA GCA G-3'
  Mouse Perp F108       5'-GCA GTC TAG CAA CCA CAT CCA G-3'
  Mouse Perp R267       5'-GCA CAG GAT GAT AAA GCC ACA G-3'
  Mouse Slpi F142       5'-GAG AAG CCA CAA TGC CGT ACT G-3'
  Mouse Slpi R378       5'-GAC TTT CCC ACA TAT ACC CTC ACA G-3'
  Mouse Pparg F682      5'-GAT ATC GAC CAG CTG AAC CCA G-3'
  Mouse Pparg R983      5'-GCA TAC TCT GTG ATC TCT TGC ACG-3'
  18S V2F               5'-AAA TCC TTT AAC GAG GAT CCA TT-3'
  18S V2R               5'-AAT ATA CGC TAT TGG AGC TGG A-3'

MiR-9 lentivirus infection
--------------------------

Lentiviral constructs were purchased from Systems Biosciences (Mountain View, CA, USA). Packaging of the lentiviral constructs was performed using the pPACKH1 Lentivector Packaging KIT (catalog no. LV500A-1) according to the manufacturer's instructions. P815 and C57 mouse mastocytoma cells and mouse BMMCs (10^5^ cells) were transduced with empty lentivirus (catalog no. CD511B-1) or pre-miR-9-3 lentivirus (catalog no. PMIRH9-3PA-1). FACS-mediated cell sorting based on GFP expression was performed 72 hours post-transduction and miR-9 expression was evaluated by real-time PCR (Applied Biosystems).

Transcriptional profiling of cells transduced with miR-9 lentivirus
-------------------------------------------------------------------

RNA was extracted from mouse BMMCs and P815 cells transduced with empty lentivirus or pre-miR-9-3 lentivirus from three separate transduction experiments using TRIzol (Invitrogen). A secondary RNA cleanup step was performed using QIAGEN RNeasy Total RNA isolation kit (QIAGEN GmbH, Hilden, Germany) and RNA integrity was assessed using RNA 6000 Nano LabChip® Kits on the Agilent Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA, USA). RNA was labeled with Cy3 using RNA ligase and hybridized to GeneChip® Mouse Gene 2.0 ST Arrays (Affymetrix, Santa Clara, CA, USA). Ratios of signals were calculated and transcripts that were up-regulated or down-regulated by at least 2-fold were identified (p \< 0.05). Data analysis, statistical analysis, and generation of gene expression heat maps were performed using Affymetrix® Transcriptome Analysis Console (TAC) Software. Prediction of miR-9 binding to the 3'-UTR of genes down-regulated by miR-9 was performed with computer-aided algorithms obtained from TargetScan (<http://www.targetscan.org>), PicTar (<http://pictar.mdc-berlin.de>), miRanda (<http://www.microrna.org>), and miRWalk (<http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk>).

Matrigel invasion assay
-----------------------

To assess the effect of miR-9 expression on invasion, cell culture inserts (8-μm pore size; Falcon) were coated with 100 μL of Matrigel (BD Bioscience, San Jose, CA, USA) to form a thin continuous layer and allowed to solidify at 37°C for 1 hour. P815 and C57 cell lines, and mouse BMMCs (5 × 10^5^/mL) transduced with control lentivirus or pre-miR-9-3 lentivirus were prepared in serum-free medium and seeded into each insert (upper chamber) and media containing 10% fetal bovine serum was placed in the lower chamber. The cells were incubated for 24 hours to permit invasion through the Matrigel layer. Cells remaining on the upper surface of the insert membrane were wiped away using a cotton swab, and cells that had migrated to the lower surface were stained with crystal violet and counted in ten independent 20× high powered fields for each sample. Experiments were repeated 3 times using samples in triplicate.

Evaluation of proliferation and apoptosis
-----------------------------------------

Changes in cell proliferation were assessed using the CyQUANT® Cell Proliferation Assay KIT (Molecular Probes, Eugene, OR, USA) as previously described \[[@B23]\]. P815 and C57 cells (15 × 10^4^) transduced with control lentivirus or pre-miR-9-3 lentivirus were seeded in 96-well plates for 24, 48, and 72 hours prior to analysis. Nontransduced P815 and C57 cells served as negative control wells. Fluorescence was measured using a SpectraMax microplate reader (Molecular Devices, Sunnyvale, CA, USA). Cell proliferation was calculated as a percentage of untransduced control cells.

Caspase-3/7 activity was determined using the SensoLyte® Homogeneous AMC Caspase- 3/7 Assay KIT (Anaspec Inc, San Jose, CA, USA) as previously described \[[@B24]\]. P815 and C57 cells (5.0 × 10^4^) transduced with either empty lentivirus or pre-miR-9-3 lentivirus were plated for 24 and 48 hours in 96-well plates prior to analysis. Fluorescence was measured on a SpectraMax microplate reader (Molecular Devices). Levels of caspase 3/7 activity were reported after subtraction of fluorescence levels of wells with medium only.

Statistical analysis
--------------------

Statistical analysis relative to miRNA expression data was performed with Statminer software (Integromics) and p-values of \<0.05 were considered statistically significant. Statistical analysis relative to mRNA expression data was performed using Affymetrix® Transcriptome Analysis Console (TAC) Software. Differential gene expression was determined by one-way ANOVA comparison test and p-values of \<0.05 were considered statistically significant. All experiments with the exception of those involving canine BMMCs were performed in triplicate and repeated 3 times. Experiments using canine BMMCs were performed in triplicate, but repeated only twice because of limited cell numbers. Data were presented as mean plus or minus standard deviation. The difference between two group means was analyzed using the Students *t*-test and a one-way analysis of variance (ANOVA) was performed for multiple variable comparisons. P-values of \<0.05 were considered significant.

Results
=======

MiRNA expression in primary canine MCTs is associated with biological behavior
------------------------------------------------------------------------------

To investigate the role of miRNA dysregulation in the biologic behavior of mast cell disease, global miRNA expression in primary canine MCTs obtained from 24 dogs diagnosed with benign tumors (n = 12) or with biologically high-grade tumors (n = 12) was evaluated using real-time PCR-based TaqMan Low Density miRNA Arrays (Applied Biosystems). An unsupervised hierarchial cluster analysis of all primary MCTs readily separated tumors into groups based on biological behavior with aggressive, highly metastatic MCTs clustering together and clinically benign MCTs clustering together separately (Figure [1](#F1){ref-type="fig"}). We identified 45 miRNAs that had significantly higher expression in biologically high-grade MCTs compared to biologically low-grade MCTs, while 7 miRNAs had lower expression (Table [2](#T2){ref-type="table"}). These data demonstrate that biologically high-grade and low-grade canine MCTs possess distinct miRNA expression signatures.

![**MiRNA expression in primary canine MCTs is associated with biological behavior.** Primary canine MCTs were obtained from dogs diagnosed with benign tumors (n = 12) or biologically high grade metastatic tumors (n = 12). Real-time PCR profiling was performed using Applied Biosystems Human TaqMan Low Density miRNA Arrays to assess mature miRNA expression in primary tumors. Unsupervised hierarchical cluster analysis separated samples into two groups based on biological behavior and demonstrate unique miRNA expression profiles associated with biologically low-grade (L) tumors or high-grade (H) tumors (P \< 0.05). (*\**) indicates primary tumor sample from a dog with a benign mast cell tumor that clustered with the biologically high grade MCT group.](1471-2407-14-84-1){#F1}

###### 

MiRNA signature associated with biologically high-grade MCTs

  **miRNA**            **Fold-change**   **p-value**   **miRNA**              **Fold-change**   **p-value**
  -------------------- ----------------- ------------- ---------------------- ----------------- -------------
  Upregulated miRNAs                                                                             
  hsa-miR-301b         4.2               0.00022       hsa-miR-520b           1.8               1.8
  hsa-miR-454          2.4               0.00032       hsa-miR-216b           4.6               0.023
  hsa-miR-9            3.2               0.0010        hsa-miR-302b           3.2               0.024
  hsa-miR-147          3.9               0.0017        hsa-miR-106b           1.6               0.026
  hsa-miR-138          2.5               0.0022        hsa-miR-618            3.0               0.027
  hsa-miR-330-5p       3.1               0.0027        hsa-miR-518f           3.2               0.029
  hsa-miR-187          5.1               0.0029        hsa-miR-182            2.8               0.030
  hsa-miR-106a         2.1               0.0044        hsa-miR-142-5p         1.7               0.031
  hsa-miR-636          2.7               0.0052        hsa-miR-301a           2.8               0.032
  hsa-miR-17           2.0               0.0057        hsa-miR-217            3.9               0.033
  hsa-miR-449b         3.2               0.0069        hsa-miR-652            2.0               0.039
  hsa-miR-130b         2.2               0.0082        hsa-miR-186            1.5               0.039
  hsa-miR-192          2.5               0.0095        hsa-miR-19a            1.8               0.040
  hsa-miR-448          3.1               0.010         hsa-miR-872            1.5               0.041
  hsa-miR-425          3.0               0.011         hsa-miR-148b           1.8               0.043
  hsa-miR-193a-3p      2.6               0.011         hsa-miR-451            2.4               0.044
  hsa-miR-18b          2.2               0.014         hsa-miR-423-5p         1.7               0.048
  hsa-miR-93           2.1               0.014         hsa-miR-191            1.5               0.049
  hsa-miR-548b-5p      2.3               0.015         Downregulated miRNAs                      
  hsa-miR-25           2.1               0.015         hsa-miR-885-5p         -4.2              0.00011
  hsa-miR-324-3p       2.3               0.017         hsa-miR-874            -5.8              0.00018
  hsa-miR-326          2.6               0.017         hsa-miR-486-3p         -4.6              0.00040
  hsa-miR-18a          3.1               0.017         hsa-miR-299-5p         -4.2              0.0020
  hsa-miR-20b          2.0               0.017         hsa-miR-488            -3.9              0.0063
  hsa-miR-194          2.8               0.019         hsa-miR-200a           -5.5              0.034
  hsa-miR-372          2.4               0.019         hsa-miR-412            -2.8              0.035

miR-9 is overexpressed in biologically high-grade canine MCTs
-------------------------------------------------------------

The miRNA array performed above identified miR-9 as overexpressed in MCTs that metastasized and resulted in death of affected dogs. This finding was confirmed by real-time PCR in which a 3.2-fold increase in miR-9 expression was identified in biologically aggressive MCTs as compared to benign MCTs (Figure [2](#F2){ref-type="fig"}A). Furthermore, miR-9 expression correlates with tumor grade and metastatic status in human breast cancer, providing further support for the idea that altered miR-9 expression may be an important regulator of aggressive biological behavior in MCTs (33). Interestingly, one of the primary tumor samples collected from a dog with a biologically low-grade MCT expressed high levels of miR-9 and the unsupervised hierarchial clustering of all 24 MCTs demonstrated that this dog's tumor clustered with the biologically high-grade tumors (Figure [1](#F1){ref-type="fig"}). Clinical data was subsequently reviewed for all dogs and it was determined that this dog had histopathologically confirmed evidence of metastatic mast cells present in a regional lymph node surgically excised at the time of primary tumor removal. Additionally, one high-grade MCT clustered with the low-grade tumors, however, this may have been due, in part, to variations in stroma/inflammatory cells within the primary tumor specimen or baseline necrosis within the tumor that influenced the proportion of tumor cells. Taken together, these findings suggest a correlation between miR-9 expression levels in primary canine MCTs and metastatic behavior.

![**MiR-9 is highly expressed in biologically high grade canine MCTs and malignant mast cell lines. (A)** Real-time PCR evaluating mature miR-9 expression in primary canine MCTs demonstrated that the mean expression of miR-9 was 3.2-fold higher in aggressive, high grade MCTs compared to benign MCTs (*p* = 0.001). (*\**) indicates primary tumor sample from a dog with a low-grade mast cell tumor that expressed high levels of miR-9 but had lymph node metastasis at the time of surgery. **(B)** Malignant canine BR and C2 mast cells, normal canine and mouse BMMCs, and malignant mouse C57 and P815 cells were cultured and real-time PCR was performed to assess miR-9 expression levels. Three independent experiments were performed and all reactions were performed in triplicate. The experiments were repeated 3 times in the cell lines and twice for normal cBMMCs.](1471-2407-14-84-2){#F2}

miR-9 expression is up-regulated in canine malignant mast cell lines
--------------------------------------------------------------------

Given the potential link between miR-9 expression and biological behavior of MCTs, we next evaluated miR-9 expression in canine (BR and C2) and murine (C57 and P815) mast cell lines and normal canine and murine BMMCs by real-time PCR. As shown in Figure [2](#F2){ref-type="fig"}B, canine mastocytoma cells exhibited higher levels of miR-9 expression when compared with normal canine BMMCs. In contrast, both mouse C57 and P815 cells and mouse BMMCs demonstrated low basal levels of miR-9. The mouse P815 mastocytoma cell line is a leukemia of mast cell origin, whereas the canine BR and C2 mastocytoma cells are derived from cutaneous tumors. The differences in the biology of these diseases may account for the observed differences in miR-9 expression in canine and murine cell lines. Low miR-9 expression in P815 cells may reflect the fact that these cells represent a true leukemia, in contrast to the BR and C2 cell lines which are derived from cutaneous tumors that would metastasize via the lymphatic system. Given prior work from our laboratory showing that the C2 line exhibits invasive behavior *in vitro* while the P815 line does not \[[@B24]\], it was possible that miR-9 expression was associated with the invasive behavior of mast cells.

Overexpression of pre-miR-9 enhances invasion of malignant mast cell lines
--------------------------------------------------------------------------

To investigate the functional consequences of miR-9 overexpression in malignant mast cell lines, we stably expressed miR-9 in the mouse P815 and C57 cell lines that exhibit low basal levels of this miRNA using an empty or pre-miR-9-3 expressing lentivirus vector. Following transduction, GFP + cells were sorted and miR-9 expression was confirmed by real-time PCR (Figure [3](#F3){ref-type="fig"}A). The invasive capacity of cells was then evaluated using a standard Matrigel invasion assay after 24 hours of culture. As shown in Figure [3](#F3){ref-type="fig"}B, enforced expression of miR-9 in C57 and P815 mast cell lines significantly enhanced their invasion compared to cells expressing empty vector.

![**Overexpression of miR-9 enhances invasion of malignant mast cells and has no effect on cell proliferation or apoptosis. (A)** Mouse P815 and C57 mast cells transduced with pre-miR-9-3 lentivirus or empty vector control were sorted to greater than 95% purity based on GFP expression. MiR-9 levels were assessed by real-time PCR in wild-type, empty vector, and miR-9 expressing cells (\*p \< 0.05). Three independent experiments were performed and all reactions were performed in triplicate. **(B)** Mouse P185 and C57 mast cells transduced with either empty vector or pre-miR-9-3 lentivirus were transferred onto cell culture inserts coated with Matrigel® for 24 hrs. After incubation, membranes were stained and cells that had invaded the membrane were counted in ten independent 20x hpf for each sample. Three independent experiments were performed and all assays were performed in triplicate wells (\*p \< 0.05). **(C)** Mouse P185 and C57 mast cells were transduced with either empty vector or pre-miR-9-3 lentivirus vector and cell proliferation was analyzed at 24, 48, and 72 hours using the CyQUANT method. Nontransduced P815 and C57 cells served as non-treated controls. Three independent experiments were performed and all samples were seeded in triplicate wells. Values are reported as percentage of untransduced control cells. **(D)** Mouse P185 and C57 mast cells transduced with either empty vector or pre-miR-9-3 lentivirus were assessed for apoptosis at 24 and 48 hours by measuring active caspase-3/7 using the SensoLyte® Homogeneous AMC Caspase-3/7 Assay kit. Relative fluorescence units are reported after subtraction of fluorescence levels of wells with medium only.](1471-2407-14-84-3){#F3}

miR-9 has no effect on cell proliferation or caspase-3,7 dependent apoptosis in malignant mast cells
----------------------------------------------------------------------------------------------------

To investigate whether overexpression of miR-9 in malignant mast cells affected their capacity to proliferate or survive, mouse C57 and P815 cell lines expressing pre-miR-9-3 lentivirus or empty vector control were cultured for 24, 48, and 72 hrs and the impact on cell proliferation and apoptosis was assessed. No effects of miR-9 on proliferation or apoptosis were observed in either cell line when compared to cells expressing empty vector (Figure [3](#F3){ref-type="fig"}C and D).

miR-9 expression enhances invasion in normal mouse BMMCs
--------------------------------------------------------

To characterize the biological consequences of miR-9 overexpression in normal mast cells, we transduced murine BMMCs with pre-miR-9-3 lentivirus or empty control vector. MiR-9 overexpression in transformed BMMCs was confirmed by quantitative real-time PCR (Figure [4](#F4){ref-type="fig"}A). To assess the effect of ectopic miR-9 expression on the invasive capacity the BMMCs, a Matrigel invasion assay was again performed. Consistent with findings in the P815 and C57 cell lines, enforced expression of miR-9 in mouse BMMCs significantly enhanced their invasive capacity compared to cells expressing empty vector (Figure [4](#F4){ref-type="fig"}B). Together, these data suggest that miR-9 promotes an invasive phenotype in mast cells.

![**Overexpression of miR-9 enhances invasion in normal mouse bone marrow-derived mast cells. (A)** Normal mBMMCs transduced with pre-miR-9-3 lentivirus or empty vector control were sorted to greater than 95% purity based on GFP expression. MiR-9 levels were assessed by real-time PCR (\*p \< 0.05). Three independent experiments were performed and all reactions were performed in triplicate. **(B)** mBMMCs transduced with either empty vector or pre-miR-9-3 lentivirus were transferred onto cell culture inserts coated with Matrigel® for 24 hrs. After incubation, cells remaining on the upper surface of the insert membrane were wiped away using a cotton swab, and cells that had migrated to the lower surface were stained with crystal violet and counted in ten independent 20x hpf for each sample. Three independent experiments were performed and all samples were performed in triplicate wells (\*p \< 0.05).](1471-2407-14-84-4){#F4}

Microarray analysis identified genes affected by miR-9
------------------------------------------------------

To gain insight into possible mechanisms underlying the observed miR-9-dependent invasive behavior of mast cells, we compared the transcriptional profiles of murine BMMCs overexpressing miR-9 to those expressing empty vector and found marked changes in gene expression (Figure [5](#F5){ref-type="fig"}). In BMMCs overexpressing miR-9, 321 transcripts were significantly up-regulated (\>2-fold) and 129 transcripts were significantly down-regulated (Table [3](#T3){ref-type="table"}, Table [4](#T4){ref-type="table"}). Bioinformatic analysis identified putative miR-9 target sites within the 3'-UTR of 40 gene transcripts that were significantly down-regulated with miR-9 overexpression, suggesting that miR-9 may directly target and regulate expression of these candidate genes (Table [3](#T3){ref-type="table"}, bolded). Real time PCR confirmed that one of these genes, peroxisome proliferator-activated receptor δ (PPARG) was down-regulated, a finding consistent with recent studies demonstrating regulation of PPARG by miR-9 through direct targeting of its 3'-UTR \[[@B25]\]. We performed real-time PCR to validate changes in gene expression for several transcripts altered by miR-9 overexpression in BMMCs. Consistent with our microarray results, we found that transcripts for HSPE and TLR7 were significantly up-regulated in BMMCs expressing miR-9, whereas transcripts for PPARG, PERP, and SLPI were significantly down-regulated compared to empty vector controls (Figure [6](#F6){ref-type="fig"}A).

![**Overexpression of miR-9 in normal mouse bone marrow-derived mast cells significantly alters gene expression.** Normal mBMMCs transduced with pre-miR-9-3 lentivirus or empty vector control were sorted based on GFP expression. RNA was harvested from mouse BMMCs transduced with empty vector or pre-miR-9-3 lentivirus from three separate transduction experiments. Transcriptional profiling was performed using Affymetrix GeneChip® Mouse Gene 2.0 ST Arrays. Hierarchical clustering was performed for 450 genes differentially expressed (p \< 0.05) in mBMMCs expressing either empty vector (EV) or miR-9 (miR9) as determined by one-way ANOVA comparison test (p \< 0.05). Mean centered signal intensities of gene-expression are depicted by the log2 of the ratio of the signals against the average signal for each comparison. Color areas indicate relative expression of each gene after log2 transformation with respect to the gene median expression (red above, green below, and black equal to the mean).](1471-2407-14-84-5){#F5}

###### 

Gene transcripts altered by miR-9 overexpression in BMMCs

  **Downregulated with miR-9 expression (BMMCs)**                  
  ------------------------------------------------- -------------- ---------------------
  1-Sep                                             Ell2           Phgdh
  **1300014I06Rik**                                 **Emp1**       **Pi16**
  **1600029D21Rik**                                 Eya2           Plk2
  2810025M15Rik                                     Fn1            **Plod2**
  5830428M24Rik                                     **Fzd4**       Ppap2b
  A2ld1                                             Gatm           **Pparg**
  Akr1c18                                           **Glrp1**      Ppic
  Alox15                                            Gm10021        Prg2
  **Amigo2**                                        Gm19524        Prss34
  **Ankrd22**                                       Gm2663         Psat1, LOC100047252
  Ankrd55                                           Gm6445         **Rbp4**
  Arfip1                                            **Gnpnat1**    Reep6
  Arg2                                              Gpc4           Retnla
  **Asb2**                                          **Gpt2**       **Rhoj**
  Asns                                              Grb10          **Scd1**
  **Atp1b1**                                        **H2-M2**      Scn7a
  Atp8b4                                            Hal            **Serpinb9b**
  Awat1                                             Hdc            Sgce
  BC100530                                          **Hgf**        **Slamf1**
  Bex1                                              Il18rap        Slc16a1
  Bri3bp                                            Il1f9          **Slc22a3**
  C87414                                            Il6st          Slc36a4
  Ccdc88c                                           Itk            **Slc43a3**
  Ccl17                                             Klf5           **Slc7a1**
  Ccl24                                             Klrb1f         Slc7a5
  **Ccl8**                                          Lama5          Slpi
  Cd209d                                            Lcn2           Snord70
  Cd24a                                             LOC100861767   Speer4e, Gm17019
  Cd36                                              LOC100862026   Stfa2
  **Cdh17**                                         Lrrk2          Stfa2l1
  Cdkn2b                                            **Mbnl3**      **Sulf2**
  **Celsr1**                                        Mcpt8          **Syne1**
  Chi3l4                                            Mgam           Taf1d
  Clec4e                                            **Mmp13**      **Tfrc**
  **Colec12**                                       Mrgpra6        **Thbs1**
  Csf3r                                             Niacr1         Tm4sf19
  Ctsg                                              Nrg1           **Tmem26**
  Ctsk                                              O3far1         Tnfrsf10b
  **Ctsl**                                          **Olr1**       **Tspan7**
  Dennd2d, 2010016I18Rik                            Pdlim1         Ube2e2
  Dnajc6                                            Perp           Vmn1r129
  **Ear2, Ear12, Ear3**                             Pga5           Zbtb10
  **Egln3**                                         Phf10          Zfp608

Bold indicates predicted miR-9 targets.

###### 

Gene transcripts altered by miR-9 overexpression in BMMCs

  **Upregulated with miR-9 expression (BMMCs)**                                         
  ----------------------------------------------- ---------------------- -------------- ---------------------
  1810011H11Rik                                   Ddx60                  Irg1           Plxna1
  2310028H24Rik                                   Dnaja4                 Itgb5          Plxnb3
  3110043O21Rik                                   Dpep2                  Kcnab3         Plxnc1
  4930420K17Rik                                   Dusp22                 Kcne3          Ppargc1a
  5033411D12Rik                                   E130215H24Rik          Kctd12         Ppfibp2
  5430435G22Rik                                   E330020D12Rik          Kctd6          Ppp1r14c
  6330415B21Rik                                   Ednra                  Khdc1a         Prdx1, LOC100862012
  9030625A04Rik                                   Egr1                   Kit            Prickle1
  9430070O13Rik                                   Emx2                   Klf2           Psd3
  9930111J21Rik2                                  Epsti1                 Klk1b1         Psg23
  A130040M12Rik                                   Esco2                  Klk1b11        Ptafr
  A230098N10Rik                                   Esr1                   Klk1b27        Ptger2
  A430084P05Rik                                   Evl                    Klk1b5         Ptplad2
  A4galt                                          F13a1                  Kmo            Ptpn13
  Abi3                                            Fabp5                  Lce6a          Qpct
  Adamtsl3                                        Fabp5, Gm3601          LOC100038947   Rasgrp3
  Adrb2                                           Fam125b                LOC100861753   Rassf4
  AI593442                                        Fam55d                 LOC100861977   Rbm47
  AI607873                                        Fam69a                 LOC100862646   Rin2
  Alcam                                           Fcgr4                  Lphn1          Rnase4, Ang
  Alpk2                                           Fkbp1b                 Lrp1           Rnase6
  Ank                                             Fos                    Lrrc16a        Rnf180
  Ano3                                            Fpr2                   Lrrc25         Rny1
  Aoah                                            Galnt10                Lrrtm1         Rps6ka2
  Apobec1                                         Galntl4                Ltf            Rsph9
  Ar                                              Gas6                   Ly6i           Rtp4
  Arhgap20                                        Gbp3                   Lyz1           Ryr3
  Arhgap24                                        Gbp4                   Maf            Scn1b
  Arhgap31                                        Gbp5                   Mast4          Scpep1
  Arl5b                                           Gbp8                   Mc1r           Serpinb8
  Asphd2                                          Gbp9                   Mecom          Siglec1
  Bank1                                           Gcet2                  Mgl2           Sirpb1a
  BC013712                                        Gdf15                  Mgll           Sirpb1b
  Bcl2a1b, Bcl2a1a                                Gdpd1                  Mir15b         Slc30a2
  Bcl2a1d, Bcl2a1a, Bcl2a1b                       Ggh                    Mir181a-1      Slc37a2
  Bhlhe41                                         Glul                   Mir3095        Slc39a4
  Bmpr2, Gm20272                                  Gm11711, Cd300lh       Mir3108        Slc40a1
  Bst1                                            Gm12250                Mir511         Slc4a11
  Bst2                                            Gm14446                Mir701         Slc6a12
  C1qb                                            Gm15915                Mlph           Slc9a9
  C1qc                                            Gm1673                 Mmp2           Slfn5
  C330018A13Rik                                   Gm1966                 Mnda, Ifi204   Smpdl3b
  C5ar1                                           Gm20099                Mpeg1          Smpx
  Cacnb4                                          Gm4759                 Mrgpra9        Snord14e, Hspa8
  Cadm3                                           Gm4951                 Mrgprb2        St3gal5
  Car8                                            Gm5431                 Ms4a4a         St6galnac3
  Ccl2                                            Gm7977                 Ms4a6b         Stab1
  Ccl4                                            Gmpr                   Ms4a6c         Stfa3
  Ccl7                                            Gna14                  Ms4a6d         Sult1a1
  Ccnd1                                           Gp1ba                  Ms4a7          Syn2
  Ccr1l1                                          Gp5                    Msr1           Syngr1
  Ccr3                                            Gpm6a                  Mtss1          Tdrd5
  Ccr5                                            Gpr55                  Nav1           Tek
  Ccrl2                                           Grap2                  Neb            Tgfbr2
  Cd14                                            H2-DMa                 Nlrp1b         Tlr1
  Cd180                                           H2-DMb2                Nlrp1c         Tlr13
  Cd200r2                                         H2-Q6,H2-Q8,LOC68395   Npy1r          Tlr7
  Cd28                                            Hey2                   Nrn1           Tlr9
  Cd300a                                          Hist1h1d               Oas2           Tmem106a
  Cd300lb                                         Hist1h1e               Oasl2          Tmem233
  Cd300ld                                         Hist1h2bg              Olfr1033       Tmem86a
  Cd86                                            Hist2h3b               Olfr110        Tnfrsf1b
  Cdh2                                            Hist2h4                Olfr111        Tns1
  Chst15, Gm10584                                 Hist3h2a               Olfr1392       Trem1
  Cited4                                          Hist4h4                Olfr1393       Trim30c
  Clec4a1                                         Hivep2                 Olfr915        Trim30d
  Clec4d                                          Hpse                   Olfr916        Trim58
  Clec4n                                          Hsd3b6                 Olfr917        Trpc6
  Cma1                                            Ier2                   Olfr918        Tsc22d3
  Cma2                                            Ifi204                 Orm3           Tspan13
  Cmklr1                                          Ifi27l2a, Ifi27l2b     P2rx7          Tspan8
  Creb5                                           Ifitm3                 P2ry6          Tubb2b
  Csf1r                                           Ifitm6                 Pcdhga10       Txk
  Ctnna2                                          Ighm                   Pcdhgb6        Ugt1a10
  Ctsh                                            Igk-V28                Pdzk1ip1       Unc93b1
  Cx3cr1                                          Il18                   Pgap1          Zbp1
  Cybb                                            Il2ra                  Pid1           Zbtb8a
  Cyp4a12a                                        Il6ra                  Pion           Zfhx3
  Dab2                                            Iqsec3                 Pld2            
  Darc                                            Irf5, Tnpo3            Pld4            
  Dbc1                                            Irf8                   Plekhm3         

Similar transcriptional profile analysis was performed using malignant mouse P815 cells and we identified 46 transcripts significantly up-regulated (\>2-fold) and 48 transcripts significantly down-regulated in the miR-9 expressing P815 cells (Table [5](#T5){ref-type="table"}). Bioinformatic analysis identified putative miR-9 target sites within the 3'-UTR of 15 gene transcripts that were significantly down-regulated following miR-9 overexpression, suggesting that miR-9 may directly regulate these genes (Table [5](#T5){ref-type="table"}, bolded). Real-time PCR demonstrated that expression of SERPINF1 and MLANA transcript was up-regulated in P815 cells overexpressing miR-9, whereas CD200R1 and CD200R4 was down-regulated compared to empty vector controls (Figure [6](#F6){ref-type="fig"}B).

![**Identification of transcripts dysregulated by miR-9 overexpression in normal murine BMMCs and P815 malignant mast cells. (A)** Transcriptional profiling of mBMMCs expressing pre-miR-9-3 lentivirus or empty vector control was performed using Affymetrix GeneChip® Mouse Gene 2.0 ST Arrays to identify genes showing differential expression (\>2-fold) with miR-9 overexpression. Real-time PCR was performed to validate changes in gene expression for transcripts (HSPE, TLR7, PERP, PPARG, SLPI) altered by miR-9 overexpression in mBMMCs (\*p \< 0.05). **(B)** Transcriptional profiling of P815 mast cells expressing pre-miR-9-3 lentivirus or empty vector control was performed as described above. Real-time PCR was performed to independently validate expression levels of genes (SERPINF1, MLANA, CD200R1, CD200R4) altered by enforced miR-9 expression in P815 cells (\*p \< 0.05). **(C)** Mouse BMMCs and P815 cells expressing pre-miR-9-3 lentivirus or empty vector control were collected and real-time PCR for IFITM3, PDZK1IP1, and CMA1 was performed (\*p \< 0.05). Three independent experiments were performed using cells from 3 separate transduction experiments and all reactions were performed in triplicate.](1471-2407-14-84-6){#F6}

###### 

Gene transcripts altered by miR-9 overexpression in P815 mast cells

  **Upregulated with miR-9 expression (P815)**   **Downregulated with miR-9 expression (P815)**
  ---------------------------------------------- ------------------------------------------------
  Ifitm3                                         Ligp1
  Pdzk1ip1                                       Ppm1j
  Cma1                                           Gbp2
  Pfkp                                           Hist2h3c1
  Serpinf1                                       Ly6a
  Trim63                                         **Cd200r1**
  As3mt                                          Gzmb
  Speg                                           **Gbp6**
  Mlana                                          Afp
  Mgl1                                           **Ifit1**
  Tmem223                                        Parp14
  Fjx1                                           Ctla2a
  Vamp5                                          Igtp
  Cthrc1                                         **Slamf1**
  Ptgis                                          Tnfrsf9
  Ass1                                           Cpa3
  Ahi1                                           Ctla2b
  Akap13                                         **Tgtp//Tgtp2**
  Prf1                                           **Rabgap1l**
  Ston2                                          Clec4e
  Hcfc1                                          Parp9
  Trak1                                          **Plekha1**
  Ankrd6                                         Il1rl1
  Atn1///Rnu7                                    Sdf2l1
  Fam122b                                        Gvin1
  Mll1                                           **Il2ra**
  Zbtb12                                         **Fcgr1**
  Ahnak                                          Gfi1
  Sec14l1                                        **Thoc1**
  Mknk2                                          Hist1h2ad
  Apobec2                                        Tmed7
  Tspan32                                        **Ugt1a1**
  Hnrnpl                                         Taf7l
  Serbp1                                         Slc13a2
  Msi2                                           Cd200r4
  Myl9                                           Vegfc
  Runx2                                          Oasl2
  Gstm1                                          **Socs3**
  Epb4.1l4b                                      677168///Isg15
  LOC100041694                                   **Ctso**
  2310051F07Rik                                  Adam8
  Arx///LOC100044440                             Samd9l
  Mest                                           1810014B01Rik
  Mpp4                                           LOC641050
  Rp131                                          Lrrc28
  Sphk1                                          **Hist2h2be**
  Ebi3                                           
                                                 **Igf1**

Bold indicates predicted miR-9 targets.

A comparison of the transcriptional profiles both from normal BMMCs and malignant P815 cells overexpressing miR-9 found that most gene transcripts altered by miR-9 were specific to normal or malignant mast cells. We identified 7 gene transcripts (IFITM3, PDZK1IP1, CMA1, MGL1, TMEM223, SLAMF1, CLEC4E) that showed similar changes in expression following miR-9 overexpression in both BMMCs and P815 cells. We performed real-time PCR to validate changes in gene expression for several transcripts altered by miR-9 overexpression, including mast cell chymase (CMA1), interferon-induced transmembrane protein 3 (IFITM3), and PDZK1 interacting protein 1 (PDZK1IP1). Consistent with our microarray results, real-time PCR confirmed that enforced miR-9 expression significantly upregulated CMA1, IFITM3, and PDZK1IP1 transcripts in mouse BMMCs and P815 cells (Figure [6](#F6){ref-type="fig"}C). These findings provide further support for the notion that miR-9 induces alterations in gene expression that may contribute to the development of an invasive phenotype.

Discussion
==========

MiRNAs regulate various biological functions in normal cells such as growth and differentiation, and they are increasingly recognized as playing critical roles in cancer development and progression. Dysregulation of miRNA expression resulting from amplification or loss of miRNAs in tumors compared to their normal tissue counterparts suggests that miRNAs can function as either oncogenes or tumor suppressor genes \[[@B13]\]. Studies evaluating miRNA expression in spontaneously occurring tumors in dogs demonstrate that similar to human cancers, alteration of miRNAs likely contributes to tumorigenesis and that high-throughput methodologies used for the study of miRNAs in human tissues can also be applied to dogs \[[@B26]-[@B32]\].

Cutaneous MCTs are the most common skin tumor in dogs; however, little is known regarding mechanisms underlying malignant transformation of these cells. The biological behavior of canine MCTs ranges from relatively benign disease cured with surgical removal to aggressive, highly metastatic tumors ultimately resulting in the death of affected dogs. While the presence of activating *KIT* mutations helps to explain the behavior of some canine MCTs, little is known regarding the potential role of miRNAs in both normal and malignant mast cells. The purpose of this study was to begin to investigate the potential role of miRNA dysregulation in canine MCTs that exhibit aggressive biologic behavior.

MiRNA expression profiling of primary canine MCTs identified unique miRNA signatures associated with aggressive MCTs as compared to benign MCTs. The unsupervised hierarchical clustering of primary cutaneous MCTs based on their miRNA expression profiles recapitulated the grouping of the tumors based on their biological behavior, supporting the notion that miRNA dysregulation is associated with the biologic behavior of canine MCTs. Furthermore, we found that miR-9 expression was significantly upregulated in aggressive MCTs compared to benign MCTs. Interestingly, miR-9 was identified as a pro-metastatic miRNA in human breast cancer cell lines through its ability to enhance cell motility and invasiveness *in vitro* and metastasis formation *in vivo*\[[@B33]\]. More recently, miR-9 expression was found to be significantly increased in paired primary tumors and distant metastatic sites, suggesting direct involvement of miR-9 in the metastatic process \[[@B34],[@B35]\]. In concordance with the potential role of miR-9 in malignant mast cell behavior, the BR and C2 canine malignant cell lines expressed high levels of miR-9 compared to normal canine BMMCs. Taken together, these data support the notion that dysregulation of miR-9 may contribute to the aggressive biologic behavior of some canine MCTs.

While activating *KIT* mutations clearly contribute to the malignant behavior of mast cells, additional cooperating or initiating genetic defects may be required for the malignant transformation and promotion of the metastatic phenotype \[[@B3]\]. Our data demonstrate that overexpression of miR-9 in the C57 and P815 mouse malignant mast cell lines and normal mouse BMMCs significantly enhanced the invasive behavior of mast cells and indicate that miR-9 induces a pattern of gene dysfunction associated with an invasive phenotype regardless of *KIT* mutation status.

While some studies have shown that miR-9 promotes metastasis formation \[[@B33],[@B36]-[@B39]\] other contrasting studies suggest that increased expression of miR-9 suppresses metastasis formation \[[@B40],[@B41]\] and that miR-9 inhibits tumor growth \[[@B42]\]. The opposing roles of miR-9 in various tissues may be explained by the expression of different mRNA targets in distinct cellular and developmental contexts. Indeed, miRNA effects do appear to be cell type/tissue specific and contextual in nature. Previous studies have demonstrated that miR-9 is overexpressed in CDX2-negative primary gastric cancers and miR-9 knockdown inhibits proliferation of human gastric cancer cell lines \[[@B43]\]. In contrast, miR-9 is downregulated in human ovarian tumor cells and overexpression of miR-9 suppresses their proliferation, in part by downregulating NFκB1 \[[@B40],[@B42]\]. Moreover, miRNA dysregulation may affect only certain aspects of cell behavior. In our studies, miR-9 expression in mast cell lines did not provide a survival advantage or prevent apoptosis, but it did alter the invasive phenotype, supporting the contextual nature of miR-9 induced effects.

To gain insight into possible mechanisms underlying the observed miR-9-dependent invasive behavior of mast cells, we evaluated the effects of miR-9 expression on the transcriptional profiles of BMMCs and P815 cells. MiR-9 modulated the expression of a large number of gene transcripts, including down-regulation of several putative miR-9 targets identified by computational prediction programs. Furthermore, down-regulation of peroxisome proliferator-activated receptor δ (PPARG) was observed in BMMCs following enforced miR-9 expression, a finding consistent with recent studies demonstrating that regulation of PPARG expression is mediated by miR-9 through direct targeting of its 3'-UTR \[[@B25]\]. To draw firm conclusions regarding direct regulation of target gene expression by miR-9, a functional approach for each gene would be required to validate whether these genes are true miR-9 targets, which although relevant, was outside the scope of this study.

Overexpression of miR-9 significantly altered gene expression in both BMMCs and P815 cells, however, most gene transcripts affected by miR-9 expression differed between normal and malignant mast cells. These observed differences likely reflect variations in the impact of miR-9 that are dependent on cellular context. In our study, we identified gene transcripts that showed similar changes in expression following miR-9 overexpression in both normal and malignant mast cells and validated several genes demonstrating significant changes in expression (interferon-induced transmembrane protein protein 3, IFITM3; PDZK1 interacting protein 1, PDZK1IP1) or implicated in promoting the metastatic phenotype (mast cell chymase, CMA1). IFITM3 belongs to a family of interferon-induced transmembrane proteins that contribute to diverse biological processes, such as antiviral immunity, germ cell homing and maturation, and bone mineralization. The function of these proteins in mast cells is currently unclear \[[@B44]\]. PDZK1IP1 is a small, non-gycosylated membrane-associated protein that localizes to the plasma membrane and Golgi apparatus. While the function of PDZK1IP1 has not been evaluated in mast cells, overexpression of PDZK1IP1 has been documented in human ovarian, breast, and prostate carcinomas and this strongly correlates with tumor progression \[[@B45],[@B46]\]. Furthermore, overexpression of PDKZK1IP1 in melanoma cell lines enhances cell proliferation, decreases apoptosis, increases cell migration and is, in part, mediated by an increase in reactive oxygen species (ROS) production \[[@B47]\].

Chymases are serine proteases possessing chymotrypsin-like activity expressed exclusively by mast cells that promote matrix destruction, tissue remodeling and modulation of immune responses by hydrolyzing chemokines and cytokines \[[@B48]\]. Given the role of chymase in the activation of matrix metalloproteases and extracellular matrix degradation, our findings suggest that miR-9 enhances invasion, in part, through increased expression chymase. Indeed, miR-9 overexpression in normal mast cells resulted in increased expression of CMA1 with a concomitant decrease in the expression of secretory leukocyte peptidase inhibitor (SLPI), a direct inhibitor of chymase \[[@B49]\]. These findings are consistent with the notion that that miR-9 promotes a pattern of gene expression contributing to enhanced invasion and suggests a role for chymase in mediating the biologic functions of miR-9.

Interestingly, miR-9 modulated the expression of other proteases in normal mast cells, including up-regulation of heparinase (HSPE). Heparinase is an endogylocosidase that functions in the degradation and release of heparan sulfate-bound growth factors \[[@B50]\]. Previous studies have shown that enzymatic cleavage of heparin sulfate by heparinase results in disassembly of the extracellular matrix and basement membrane dissolution, inducing structural modifications that loosen the extracellular matrix barrier and enable cell invasion \[[@B51]\]. Heparinase increases tumor invasion in both cell lines and spontaneous tumor models, through both extracellular matrix remodeling and increased peritumoral lymphangiogenesis \[[@B52]\]. Our data show that normal mast cells overexpressing miR-9 exhibit markedly increased HSPE expression, supporting the assertion that miR-9 may promote the metastatic phenotype by enhancing the proteolytic activity of a number of proteases important in physical remodeling of the extracellular matrix and activate mediators responsible for cell dissemination.

The present study investigated alterations in gene transcript expression affected by miR-9; however, these changes were not demonstrated at the protein level. Gene expression does not directly correlate with changes at the protein level and miRNAs may suppress protein expression by post-transcriptional silencing mechanisms that are not reflected in transcriptional profiling analyses. Furthermore, inhibition of miR-9 in canine mast cell lines would provide further convincing evidence of its importance in mast cell invasion. As such, identifying proteins altered by miR-9 that promote cell invasion and validating these targets in canine cell lines/tumors represents an area of ongoing investigation.

Conclusion
==========

In summary, the work presented here is the first to demonstrate that unique miRNA expression profiles correlate with the biological behavior of canine MCTs. Furthermore, overexpression of miR-9 is associated with aggressive biologic behavior of canine MCTs, possibly through the promotion of a metastatic phenotype as demonstrated by enhanced invasive behavior of normal and malignant mast cells and alteration of gene expression profiles associated with cellular invasion in the presence of enforced miR-9 expression. Future work to dissect the exact mechanisms through which miR-9 exerts the invasive phenotype is ongoing with the ultimate goal of identifying potential druggable targets for therapeutic intervention.
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